

Nuclear Receptors

TH301

Isoform-selective stabilizer of the circadian clock protein CRY2.¹ Dose-dependently lengthened the circadian period of Bmal1-dLuc and Per2-dLuc reporter cells.

Product No: 10-3909 5 mg 25 mg

SLU-PP-332

Estrogen receptor-related receptor pan-agonist that acts as an exercise mimetic via increased mitochondrial function and cellular respiration in skeletal muscle.²

Product No: 10-3948 5 mg 25 mg

24(S)-Hydroxycholesterol

Endogenous agonist for the liver X receptor (LXR).³ CFS levels of 24(S)-hydroxycholesterol are a potential biomarker for Alzheimer's disease and cognitive impairment.⁴

Product No: 10-1331 1 mg 5 mg

SR1 (StemRegenin 1)

Arylhydrocarbon receptor (AhR) antagonist that extends the pluripotency of hematopoietic stem cells.⁵

Product No: 10-4508 1 mg 5 mg

24,25-Epoxycholesterol

Endogenous agonist for nuclear receptor LXR.³ Controls cellular cholesterol homeostasis.⁶ Promotes neural development in zebra fish as well as dopaminergic differentiation of embryonic stem cells.⁷

Product No: 10-1330 1 mg 5 mg

SI-2

Potent inhibitor of steroid receptor coactivator-3.⁸ Inhibits breast cancer proliferation and cancer stem cell tumorsphere formation.⁹

Product No: 10-3903 5 mg 25 mg

SR0987

SR0987 is a ROR γ t agonist that drives proliferation of T_H17 cells and decreases levels of the immune checkpoint protein PD-1.¹⁰

Product No: 10-4008 5 mg 25 mg

Ro 41-5253

Selective RAR α antagonist.¹¹ Binds RAR α without inducing transcription or influencing RAR/RXR heterodimerization and DNA binding.¹² Cell permeable.

Product No: 10-4504 5 mg 25 mg

SR8278


SR8278 is an antagonist of the nuclear heme receptor REV-ERB α .¹³

Product No: 10-1506 5 mg 25 mg


SR9009

SR9009 is an agonist of REV-ERB α .¹⁴ It inhibits circadian activity and core clock gene expression. Specifically lethal to cancer cells and oncogene-induced senescent cells without effecting normal cells.¹⁵

Product No: 10-1511 5 mg 25 mg



TH301



SLU-PP-332

REFERENCES

1. Miller *et al.* (2020) *Nat. Chem. Biol.* **16** 676
2. Billon *et al.* (2023) *ACS Chem. Biol.* **18** 756
3. Chawla *et al.* (2001) *Science* **294** 1866
4. Leoni and Caccia (2013) *Biochem.Pharmacol.* **86** 26
5. Boitano *et al.* (2010) *Science* **329** 1354
6. Brown *et al.* (2009) *Int.J.Biochem.Cell Biol.* **41** 744
7. Theofilopoulos *et al.* (2013) *Nature Chem.Biol.* **9** 126
8. Song *et al.* (2016) *PNAS* **113** 4970
9. Rohira *et al.* (2017) *Cancer Res.* **77** 4293 924
10. Chang *et al.* (2016) *ACS Chem. Biol.* **11** 1012
11. Apfel *et al.* (1992) *PNAS* **89** 7129
12. Toma *et al.* (1998) *Int.J.Cancer* **78** 86
13. Kojetin *et al.* (2011) *ACS Chem.Biol.* **6** 131
14. Solt *et al.* (2012) *Nature* **485** 62
15. Sulli *et al.* (2018) *Nature* **553** 351